The misuse of existing antibiotics in clinical practice and the introduction of antibiotics into the environment in combination with the inherently adaptive nature of microorganisms has led to a major global health crisis with the evolution of antibiotic-resistant organisms. The crisis is driving demand for the development of new antibacterial therapies for the treatment of drug-resistant and emerging bacterial pathogens.
This webinar will address the steps necessary to bring an antibacterial therapeutic from discovery to clinical trials and will discuss basic strategies for the development and execution of a pre-clinical antibacterial drug development program.
About the Presenter
Dr. Parsley has over twenty-five years of experience in microbiology, molecular biology and infectious disease research with emphasis on pathogen-host interactions, viral and microbial replication/gene expression and pathogen resistance. Prior to joining Noble, Dr. Parsley was Chief Scientific Officer at SynPhaGen, LLC. Prior to founding SynPhaGen, Dr. Parsley held various positions at a CRO and managed multiple research projects for the development of antimicrobial agents for viruses, bacteria, and fungi, and designed, developed and optimized novel molecular assays in support of antiinfective programs. Dr. Parsley received his Ph.D. in Microbiology and Molecular Genetics from the University of California, Irvine and a B.A. in Microbiology from the University of California, San Diego.
After registering, you will receive a confirmation email containing information about joining the webinar.